SuperworthNautilus Biotechnology NAUT
- Market cap
- $412.3M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −12.6%
Nautilus Biotechnology's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | $0 | n/a | n/a | n/a | $190K | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $0 | n/a | n/a | n/a | $15K |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $0 | n/a | n/a | n/a | $175K |
| R&D | $12M+25% | $12.5M+30% | $12.9M+19% | $12.4M+4% | $12.3M+2% | $12.8M+3% | $11.5M−11% | $10.4M−16% | $9.6M−22% | $9.6M−25% | $9.7M−16% | $9.6M−8% |
| SG&A | $7.1M+13% | $7.5M+12% | $8.7M+21% | $8.4M+18% | $6.8M−4% | $7.2M−5% | $7.3M−16% | $6.7M−20% | $5.9M−14% | $5.8M−18% | $6.4M−12% | $6.3M−6% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$15.9M+13% | −$17M+27% | −$18.7M+25% | −$18M+14% | −$16.4M+4% | −$17.6M+3% | −$16.6M−11% | −$15M−17% | −$13.6M−18% | −$13.8M−22% | −$14.7M−12% | −$14.5M−4% |
| −$0.13+18% | −$0.14+27% | −$0.15+25% | −$0.14+8% | −$0.13+0% | −$0.14+0% | −$0.13−13% | −$0.12−14% | −$0.11−15% | −$0.11−21% | −$0.12−8% | −$0.11−8% | |
| 124.9M+0% | 125M+0% | 125.1M+0% | 125.3M+1% | 125.5M+0% | 125.8M+1% | 126.1M+1% | 126.2M+1% | 126.3M+1% | 126.4M+1% | 126.6M+0% | 127.1M+1% |
Gross profit: Q2 FY25 and Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY20: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20: 6 months less the 3 months printed beside them.
Net income: Q1 FY20: 6 months less the 3 months printed beside them.
EPS, diluted: 7 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Nautilus Biotechnology's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NAUTNautilus Biotechnology | $412.3M | n/m | n/a | n/m | n/m | n/m | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| CDNACareDx | $3.6B | 33.4× | 19.1× | 7.8× | +34% | 24.2% | |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | 6.9× | +17% | 20.4% | |
| Peer median | $2B | 61.0× | 39.6× | 5.2× | +13% | 12.3% |
More on Nautilus Biotechnology
Each number over time
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .